Project Grant R01HL173147
Award Date
12/10/24
Completion Date
11/30/28
Dollars Obligated
$741K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research program supports research to better understand the pathophysiology of primary ciliary dyskinesia (PCD) and develop potential treatments. Key activities include: Investigating the early pathogenesis of PCD, studying metabolic changes due to impaired ciliary function, and evaluating whether gene addition therapy can restore ciliary function and impact PCD disease...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $629,319 to Emory University to investigate methods for overcoming refractory cystic fibrosis (CF) defects. The research aims to identify cellular targets that can ameliorate disease by correcting basic defects resulting from premature termination codons (PTCs) in the CF transmembrane conductance regulator (CFTR) gene. Key research activities include...
This Project Grant award of $701,440 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at Yale University to investigate the function of the RUVBL1-RUVBL2 proteins in the assembly of dynein arms, which are critical components of motile cilia. The research aims to elucidate the mechanism of RUVBL1-RUVBL2 foci formation and systematically define the components and biochemical relationships of the...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Northwestern University provides $798,958 to conduct research on the molecular mechanisms underlying the link between primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD) after lung transplantation. The key objectives are to: 1) Determine whether activation of the integrated stress response (ISR) in the alveolar epithelium impairs repair after...
This $701,842 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research at the University of South Florida to investigate the role of the CDK13 gene in the development of congenital heart defects. The project aims to utilize mouse models and human induced pluripotent stem cell-derived cardiomyocytes to better understand how mutations in CDK13 disrupt RNA processing and lead to cardiac...
This $2,803,961 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a collaborative research effort to investigate the mechanisms underlying primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD) in lung transplant recipients. The research team at Northwestern University will conduct four interrelated projects to better understand the role of lung-restricted alloantibodies,...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $802,762 to The University of Texas Southwestern Medical Center to investigate the genetic mechanisms underlying congenital heart disease (CHD). The key objectives are to: 1) Define the transcription factors and gene regulatory networks controlling human cardiac development; 2) Identify and characterize genetic variants regulating cardiac gene programs; and 3)...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,057,973 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Johns Hopkins University to conduct research on modeling fetal lung development in congenital diaphragmatic hernia (CDH). The research aims to investigate the role of the YAP/TAZ mechanosensing pathway in CDH lung hypoplasia using mouse models, human lung organoids, and large animal fetal models. The research teams led by Shaun Kunisaki, Jason...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to support research on the genetic landscape of childhood interstitial and diffuse lung diseases (CHILD). The key objectives are to: 1) Define molecular profiles of 300 CHILD lung biopsy samples to identify patient clusters with similar underlying causes, 2) Analyze whole exome sequence data from 400 children with...
This Project Grant award of $5,715,866 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies that substantially reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The multi-year program, which began in September 2024, focuses on investigating the transcriptomic, genetic, epigenetic, metabolic, and environmental signatures that contribute to the initiation and early...